We are experiencing some temporary issues. The market data on this page is currently delayed. Please bear with us as we address this and restore your personalized lists.
Company Earnings Calendar - Yahoo Finance
Prev
- 2JunSun23 Earnings
- 3JunMon554 Earnings
- 4JunTues638 Earnings
- 5JunWed789 Earnings
- 6JunThu666 Earnings
- 7JunFri206 Earnings
- 8JunSat
Next
Earnings on Sun, Jun 021-23 of 23 results
| Symbol | Company | Event Name | Earnings Call Time | EPS Estimate | Reported EPS | Surprise(%) |
|---|---|---|---|---|---|---|
| KRNTY | Krones AG | Annual Shareholders Meeting | TAS | - | - | - |
| ADBCF | Adbri Ltd | Annual Shareholders Meeting | TAS | - | - | - |
| LLY | Eli Lilly and Co | Oncology ASCO Investor Event | TAS | - | - | - |
| KRNNF | Krones AG | Annual Shareholders Meeting | TAS | - | - | - |
| PAIYY | Aesthetic Medical International Holdings Group Ltd | Q1 2024 Earnings Release | Before Market Open | - | - | - |
| NVSEF | Novartis AG | ASCO Investor Event | TAS | - | - | - |
| ADLDY | Adbri Ltd | Annual Shareholders Meeting | TAS | - | - | - |
| NVS | Novartis AG | ASCO Investor Event | TAS | - | - | - |
| CRYIF | Crystal International Group Ltd | Annual Shareholders Meeting | TAS | - | - | - |
| GFOO | Genufood Energy Enzymes Corp | Q2 2024 Earnings Release | After Market Close | - | - | - |
| CTRYF | Country Garden Holdings Co Ltd | Annual Shareholders Meeting | TAS | - | - | - |
| ZHAOF | Zhaojin Mining Industry Co Ltd | Annual Shareholders Meeting | TAS | - | - | - |
| UVRBF | Universal Robina Corp | Annual Shareholders Meeting | TAS | - | - | - |
| HLDCY | Henderson Land Development Co Ltd | Annual Shareholders Meeting | TAS | - | - | - |
| HLDVF | Henderson Land Development Co Ltd | Annual Shareholders Meeting | TAS | - | - | - |
| CTRYY | Country Garden Holdings Co Ltd | Annual Shareholders Meeting | TAS | - | - | - |
| CDEXF | Cardiex Ltd | CardieX Ltd Extraordinary Shareholders Meeting | TAS | - | - | - |
| UVRBY | Universal Robina Corp | Annual Shareholders Meeting | TAS | - | - | - |
| DRSHF | DroneShield Ltd | Extraordinary Shareholders Meeting | TAS | - | - | - |
| HDVTY | Henderson Investment Ltd | Annual Shareholders Meeting | TAS | - | - | - |
| MBLMF | Mobilum Technologies Inc | Q4 2023 Earnings Release | TAS | - | - | - |
| STTTF | Splitit Ltd | Annual Shareholders Meeting | TAS | - | - | - |
| NBTX | Nanobiotix SA | Investor Call | TAS | - | - | - |
Motley FoolThis Is the Biggest Risk for Eli Lilly and Novo Nordisk Investors
These stocks are trading at sky-high valuations which could make them vulnerable to sell-offs.
Investor's Business DailyS&P 500 Giants Lead Five Healthy Stocks Near Buy Points
Eli Lilly, Novo Nordisk, Vertex Pharmaceuticals, Intuitive Surgical and Universal Health are all trading in or near buy zones. Medical stocks are often viewed as defensive growth stocks, because their growth is insulated from economic swings due to the government or insurance covering most of the costs. Eli Lilly is in a buy zone while weight-loss drug rival and fellow IBD Leaderboard member Novo Nordisk is setting up.
PR NewswireUpdated Data from the Phase 1/2 Study of Olomorasib in KRAS G12C-Mutant Advanced Solid Tumors Presented at the 2024 ASCO® Annual Meeting
Eli Lilly and Company (NYSE: LLY) today announced updated data from the Phase 1/2 clinical trial evaluating olomorasib as a monotherapy in patients with KRAS G12C-mutant advanced solid tumors and in combination with Merck's anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in patients with KRAS G12C-mutant advanced non-small cell lung cancer (NSCLC). Olomorasib is an investigational, oral, potent, and highly selective second-generation inhibitor of the KRAS G12C protein. These data will be shared in o
ZacksTop Research Reports for Eli Lilly, T-Mobile & BHP
Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), T-Mobile US, Inc. (TMUS) and BHP Group Limited (BHP).
ZacksNovartis (NVS) Reports Positive Long-Term Data on CSU Drug
Novartis (NVS) reports phase III data that confirm sustained efficacy and long-term safety of oral remibrutinib in chronic spontaneous urticaria.
Insider MonkeyIs Eli Lilly And Co (NYSE:LLY) the Best Weight Loss Stock to Buy in 2024?
We recently published a list of Jim Cramer’s Top 10 Stock Picks for June. Since Eli Lilly And Co (NYSE:LLY) ranks higher in the list, the stock deserves a deeper look. But first, let’s see what Cramer was talking about during his programs earlier this week. Jim Cramer in a latest program lamented over Salesforce’s […]
GlobeNewswireNovartis Scemblix® Phase III data first to show superior efficacy with a favorable safety and tolerability profile vs. standard-of-care TKIs in adults with newly diagnosed CML
Phase III ASC4FIRST trial met both primary endpoints with clinically meaningful and statistically significant results; Scemblix® (asciminib) demonstrated superior MMR rates at week 48 vs. investigator-selected SoC TKIs (imatinib, nilotinib, dasatinib and bosutinib) (67.7% vs. 49.0%) and imatinib alone (69.3% vs. 40.2%)1 Scemblix also demonstrated a favorable safety and tolerability profile vs. imatinib and 2G TKIs, with fewer grade ≥3 AEs, dose adjustments, and half the rate of AEs leading to tr
Clinical Trials ArenaNovartis reports Phase III data for trials of remibrutinib to treat CSU
The safety profile of remibrutinib was found to be favourable and consistent throughout the 52-week trial period.
BloombergGoldman Sees Obesity-Drug Market Growing to $130 Billion by 2030
(Bloomberg) -- Goldman Sachs Group Inc. sees growing potential for the global market for weight-loss drugs by the end of the decade.Most Read from BloombergWall Street Billionaires Are Rushing to Back Trump, Verdict Be DamnedDonald Trump Becomes First Former US President Guilty of CrimesTrump Is Guilty on All Counts in Hush-Money Case. Now What?South Africa Election Results With 29% Voting Districts InFed’s Favored Inflation Gauge Cools, Spending Unexpectedly DropsThe obesity market — currently
BioPharma DiveNovartis study points to larger role for targeted leukemia drug
Results from a trial called ASC4FIRST show Scemblix outperformed Gleevec and other drugs in treating newly diagnosed chronic myeloid leukemia.